Histogen Inc
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its prec… Read more
Market Cap & Net Worth: Histogen Inc (HSTO)
Histogen Inc (NASDAQ:HSTO) has a market capitalization of $115.34K ($115.34K) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #41379 globally and #13455 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Histogen Inc's stock price $0.03 by its total outstanding shares 4271760 (4.27 Million).
Histogen Inc Market Cap History: 2015 to 2025
Histogen Inc's market capitalization history from 2015 to 2025. Data shows change from $2.46 Billion to $115.34K (-67.33% CAGR).
Histogen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Histogen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
69.70x
Histogen Inc's market cap is 69.70 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.50 Billion | $799.05K | -$29.73 Million | 5634.74x | N/A |
| 2017 | $3.95 Billion | $35.38 Million | -$17.40 Million | 111.57x | N/A |
| 2018 | $1.48 Billion | $33.59 Million | -$18.01 Million | 44.01x | N/A |
| 2019 | $341.74 Million | $11.30 Million | -$4.90 Million | 30.23x | N/A |
| 2020 | $64.76 Million | $2.06 Million | -$25.77 Million | 31.45x | N/A |
| 2021 | $28.42 Million | $919.00K | -$14.40 Million | 30.93x | N/A |
| 2022 | $3.55 Million | $3.77 Million | -$10.48 Million | 0.94x | N/A |
| 2023 | $1.32 Million | $19.00K | -$12.38 Million | 69.70x | N/A |
Competitor Companies of HSTO by Market Capitalization
Companies near Histogen Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Histogen Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Histogen Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Histogen Inc's market cap moved from $2.46 Billion to $ 115.34K, with a yearly change of -67.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $115.34K | -2.53% |
| 2024 | $118.33K | -91.06% |
| 2023 | $1.32 Million | -62.65% |
| 2022 | $3.55 Million | -87.53% |
| 2021 | $28.42 Million | -56.11% |
| 2020 | $64.76 Million | -81.05% |
| 2019 | $341.74 Million | -76.88% |
| 2018 | $1.48 Billion | -62.55% |
| 2017 | $3.95 Billion | -12.33% |
| 2016 | $4.50 Billion | +82.99% |
| 2015 | $2.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Jan 23rd, 2026 the market cap of Histogen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $115.34K USD |
| MoneyControl | $115.34K USD |
| MarketWatch | $115.34K USD |
| marketcap.company | $115.34K USD |
| Reuters | $115.34K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.